Subscribe: MedWorm: Cancer Therapy
http://www.medworm.com/rss/medicalfeeds/therapies/Cancer-Therapy.xml
Preview: MedWorm: Cancer Therapy

MedWorm: Cancer Therapy News



MedWorm.com provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Cancer Therapy



Last Build Date: Thu, 22 Feb 2018 09:28:40 +0100

 



Precision cancer therapy effective in both children and adults

Wed, 21 Feb 2018 05:00:00 +0100

(Children's Hospital Los Angeles) Three quarters of patients, both adults and children, with a variety of advanced cancers occurring in different sites of the body responded to larotrectinib, a novel therapy that targets a specific genetic mutation. Results of a phase 1/2 trial have been published in the New England Journal of Medicine. Unlike most cancer therapies, this oral treatment is based on the genetic traits of the tumor and not the organ where the cancer originated. (Source: EurekAlert! - Cancer)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Zimbabwe:Scrap Cancer Therapy Charges - First Lady

Thu, 15 Feb 2018 07:12:13 +0100

[The Herald] First Lady Auxillia Mnangagwa has appealed to Government to scrap radiotherapy charges for cancer patients. Addressing hundreds of people in Masvingo, she said the current $400 charge per session was beyond the reach of many cancer patients. (Source: AllAfrica News: Health and Medicine)



Warning from the American Heart Association: Breast cancer treatments, such as radiation and chemo, can cause heart failure

Wed, 14 Feb 2018 12:18:09 +0100

(Natural News) Sometimes the cure is worse than the ailment, the saying goes, and a new warning from the American Heart Association is shedding light on the quandary many women face when weighing breast cancer treatment against the potential side effects. According to the group, some of the most popular breast cancer therapies can actually... (Source: NaturalNews.com)



Possible new principle for cancer therapy

Wed, 14 Feb 2018 05:00:00 +0100

(Karolinska Institutet) A study published in Science Translational Medicine shows that small molecules that specifically inhibit an important selenium-containing enzyme may be useful in combating cancer. When researchers at Karolinska Institutet in Sweden treated cancer in mice using these molecules, they observed rapid tumoricidal effects. Researchers now hope that this new principle for cancer treatment will eventually be developed for use in humans. (Source: EurekAlert! - Cancer)



Funding to lead team-based investigation of gynecologic cancer therapies

Fri, 09 Feb 2018 05:00:00 +0100

(University of Pennsylvania School of Medicine) E. John Wherry, PhD, a cancer and immunology researcher at the Perelman School of Medicine at the University of Pennsylvania and one of the most highly cited investigators in his field, has been awarded a 'Convergence 2.0' research grant by Stand Up to Cancer (SU2C) to investigate immune system response to cancers. (Source: EurekAlert! - Cancer)



Potential new target for reducing osteoporosis risk in men

Fri, 02 Feb 2018 12:00:00 +0100

Researchers have identified a new regulator of vitamin D metabolism that could be targeted to reduce the risk of osteoporosis in men undergoing prostate cancer therapy, according to a study published in theJournal of Molecular Endocrinology.Medical Xpress (Source: Society for Endocrinology)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Breast cancer therapies can raise heart risks, doctors warn

Thu, 01 Feb 2018 22:37:59 +0100

Some breast cancer treatments may raise the risk of heart disease, according to a warning issued by the American Heart Association. Patients should still undergo lifesaving treatments but not neglect their heart health, doctors say. (Source: CNN.com - Health)



Breast cancer treatments could cause heart failure

Thu, 01 Feb 2018 21:06:13 +0100

A new scientific statement issued today by the American Heart Association reveals some breast cancer therapies can increase the risk of heart arrhythmia and disease. (Source: the Mail online | Health)



Doctors warn of heart risk from some breast cancer therapies

Thu, 01 Feb 2018 20:13:04 +0100

Health experts sound a warning about potential side effects of a growing number of breast cancer ​ treatments (Source: Health News: CBSNews.com)



Varian to Acquire Embattled Sirtex for $1.3B

Thu, 01 Feb 2018 04:20:39 +0100

Varian Medical Systems has revealed plans to acquire interventional oncology specialist Sirtex Medical for $1.3 billion. The proposed acquisition comes about a year after the New South Wales, Australia-based company fired CEO Gilman Wong, following an investigation into his share trading. In January 2017, the Sydney Morning Herald reported Wong was terminated after an investigation revealed he received $2.1 million from the sale of shares in Sirtex about one day after he told investors at the company’s annual general meeting that the company expected “double-digit” dose sales in 2017. Wong was replaced in June 2017 by 20-year industry veteran Andrew McLean. Network with your colleagues in medtech at the MD&M West Conference and Expo, February 6–8, 2018, in Anaheim, CA. Use p...



Stealth virus for cancer therapy

Wed, 31 Jan 2018 05:00:00 +0100

(University of Zurich) Scientists from the University of Zurich have redesigned an adenovirus for use in cancer therapy. To achieve this they developed a new protein shield that hides the virus and protects it from being eliminated. Adapters on the surface of the virus enable the reconstructed virus to specifically infect tumor cells. (Source: EurekAlert! - Cancer)



Potential new target for reducing osteoporosis risk in men

Tue, 30 Jan 2018 05:00:00 +0100

This study has identified a previously unknown link between male sex hormone levels and vitamin D that may have future therapeutic value for treating related deficiencies of the vitamin. (Source: EurekAlert! - Cancer)



NUS researchers develop wireless light switch for targeted cancer therapy

Mon, 29 Jan 2018 05:00:00 +0100

(National University of Singapore) A team of scientists from the National University of Singapore has developed a way to wirelessly deliver light into deep regions of the body to activate light-sensitive drugs for photodynamic therapy (PDT). This technology could potentially enable PDT to be used to treat a wider range of cancers, such as brain and liver cancer. (Source: EurekAlert! - Cancer)



BioPharma Veterans Launch New Oncology Company

Thu, 25 Jan 2018 15:20:56 +0100

Partner Therapeutics to focus on commercial and late-stage cancer therapies BOSTON, Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Biotech and pharmaceutical executives Robert Mulroy and Dr. Debasish Roychowdhury announced today the launch ... Biopharmaceuticals, Oncology, Personnel Partner Therapeutics (Source: HSMN NewsFeed)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Celgene Buys Juno Therapeutics: A Risky $9B Bet

Mon, 22 Jan 2018 21:23:00 +0100

Celgene has gone “all-in” on CAR-T cancer therapies, forking out $9 billion to acquire Juno Therapeutics amid much fanfare. Critics worry this wager may fail to help the biotech giant fill the gaps in its revenue stream. (Source: Forbes.com Healthcare News)



Celgene to buy Juno for $9 billion to boost CAR-T expertise

Mon, 22 Jan 2018 13:53:53 +0100

(Reuters) - Celgene Corp announced a $9 billion cash buyout of Juno Therapeutics Inc on Monday as it moves to cement its position as a key player in a new range of cancer therapies. (Source: Reuters: Health)



Multifunctional platform for the delivery of gene therapeutics

Mon, 22 Jan 2018 05:00:00 +0100

(Wiley) Gene editing is one of the hottest topics in cancer research. A Chinese research team has now developed a gold-nanoparticle-based multifunctional vehicle to transport the 'gene scissors' to the tumor cell genome. As the authors report in the journal Angewandte Chemie, their nonviral transport and release platform of gene-editing systems has the additional advantage of combining hyperthermal cancer therapy with genetic modification. (Source: EurekAlert! - Cancer)



Boosting cancer therapy with cross-dressed immune cells

Mon, 22 Jan 2018 05:00:00 +0100

(Ecole Polytechnique F é d é rale de Lausanne) Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods. (Source: EurekAlert! - Cancer)



Immediate breast reconstruction after mastectomy does not delay start of chemotherapy or radiotherapy – but may increase risk of complications and readmission

Fri, 19 Jan 2018 10:34:00 +0100

Having immediate reconstruction following a mastectomy does not delay the start of a patient ’ s adjuvant breast cancer therapy but may increase the likelihood of complications requiring hospital readmission in the first six weeks after surgery, according to new research led by researchers at the University of Bristol and the Royal Liverpool University Hospital presented at the UK Interdisciplinary Breast Cancer Symposium (UKIBCS) in Manchester – hosted by leading charity Breast Cancer Now. (Source: University of Bristol news)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Dulling cancer therapy's double-edged sword

Wed, 17 Jan 2018 05:00:00 +0100

(Boston Children's Hospital) Researchers have discovered a very promising new pathway to preventing tumor recurrence -- 'resolvins' could be used in complement with chemotherapy, radiation and targeted therapies to stave off the tumor-promoting effects of dead cancer cell debris. (Source: EurekAlert! - Cancer)



Key player in cell metabolism identified

Tue, 16 Jan 2018 05:00:00 +0100

(Institute for Research in Biomedicine (IRB Barcelona)) Published in Nature Cell Biology (NCB), the study shows that the EXD2 protein is critical for the mitochondria, the cell's powerhouses, to produce energy. This protein was previously thought to be located in the cell nucleus and to be involved in DNA repair. The results contribute to our basic understanding of mitochondria and suggest that EXD2 could be important for fertility and represent a potential target for cancer therapy. (Source: EurekAlert! - Medicine and Health)



Precision Medicine Requires Targeted Cancer Therapies, but Payers Reluctant to Pay for Some Genetic Testing Needed to Match a Patient with Right Drug

Fri, 12 Jan 2018 11:00:28 +0100

Clinical labs and pathology groups know how advances in targeted therapies and genomics far outpace providers’ and patients’ ability to know how best to use and pay for them One fascinating development on the road to precision medicine is that many new cancer drugs now in clinical trials will require a companion genetic test to […] (Source: Dark Daily)



Deep sea creatures provide a guiding light in the quest to develop cancer therapies

Tue, 09 Jan 2018 05:00:00 +0100

(University of Southern California - Health Sciences) Scientists at the Keck School of Medicine of USC use enzymes responsible for marine animal bioluminescence to help researchers test whether cancer immunotherapies work. (Source: EurekAlert! - Cancer)



Top 5 Practice-Changing Developments in Lung Cancer in 2017 Top 5 Practice-Changing Developments in Lung Cancer in 2017

Mon, 08 Jan 2018 16:07:00 +0100

Last year was a big one for lung cancer therapy developments. Here are five of the most clinically relevant, with a brief commentary by lung cancer expert H. Jack West, MD.Medscape Oncology (Source: Medscape Today Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Hot flashes caused by cancer therapy can be prevented, treated

Mon, 08 Jan 2018 15:09:36 +0100

(Reuters Health) - Cancer patients with hot flashes related to hormone therapy should know that these uncomfortable symptoms can be managed, according to a recently published resource for patients. (Source: Reuters: Health)



Researchers Discover Link between Gut Bacteria and the Effectiveness of Certain Cancer Drugs; Knowledge May Lead to New Types of Clinical Laboratory Tests

Mon, 08 Jan 2018 11:00:55 +0100

Microbiome is once again leading scientists toward a new understanding of how human gut bacteria can impact the efficacy and side-effects of certain cancer therapies Anatomic pathology researchers already know that a person’s genetics can affect the results of cancer treatments. Now it is becoming clear that a patient’s microbiome—which includes gut bacteria—may also impact […] (Source: Dark Daily)



Novartis breast cancer therapy gets FDA breakthrough designation

Wed, 03 Jan 2018 06:56:34 +0100

ZURICH (Reuters) - Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday. (Source: Reuters: Health)



Berry gives boost to cervical cancer therapy

Fri, 29 Dec 2017 09:00:00 +0100

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most common treatments for cervical cancer is radiation. While radiation therapy destroys cancer cells, it also destroys nearby healthy cells. University of Missouri School of Medicine researchers studied in vitro human cancer cells to show that combining blueberry extract with radiation can increase the treatment's effectiveness. (Source: World Pharma News)



Cardiovascular Complications of Cancer Therapy Cardiovascular Complications of Cancer Therapy

Wed, 27 Dec 2017 05:14:41 +0100

Cancer therapy can have serious cardiovascular complications. Learn about the cardiac effects of commonly used chemotherapies and how best to prevent and manage them in this overview.Journal of the American College of Cardiology (Source: Medscape Today Headlines)



How a tumor grows can predict which cancer drug will work best

Fri, 22 Dec 2017 16:58:20 +0100

New research out of USC suggests the growth patterns specific to a tumor can predict which cancer therapies are likely to work best. (Source: Health News - UPI.com)






How a tumor grows can predict response to cancer therapy

Thu, 21 Dec 2017 05:00:00 +0100

(University of Southern California) Individual tumors respond differently to cancer drugs, if at all. Until now, it remained a mystery why tumors have different reactions to the exact same therapy. But a new study at the USC Viterbi School of Engineering finds that tumor growth properties can influence response to cancer drugs. (Source: EurekAlert! - Cancer)



Skyline Medical to take 20% stake in Helomics, license Illumina ’ s gene sequencing tech

Wed, 20 Dec 2017 15:08:18 +0100

Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which combined with its existing right to convert a $500,000 loan would give it a 25% stake in the Pittsburgh-based precision diagnostics and contract research firm. Yesterday’s $1.14 closing price for Skyline stock would value the 20% stake at nearly $1.3 million. “Our strategic growth plan is to invest in, and partner with, leading edge players in emerging areas of the healthcare indus...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Expensive new cancer therapy may be cost effective

Wed, 20 Dec 2017 05:00:00 +0100

(University of Colorado Anschutz Medical Campus) Researchers from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, selected to estimate the cost-effectiveness of the newly approved CAR-T therapies, have found the clinical benefit may justify the expensive price. (Source: EurekAlert! - Cancer)



Individuals in the US diagnosed with cancer are 2.7 times more likely to declare bankruptcy than individuals without cancer, study finds

Wed, 20 Dec 2017 05:00:00 +0100

This study, published in Oncotarget, titled " A global comparison of the cost of patented cancer drugs in relation to global differences in wealth " identifies several critical factors impacting cancer patients. (Source: EurekAlert! - Cancer)



Roswell Park to develop new cancer therapies with $1M state grant

Fri, 15 Dec 2017 17:35:01 +0100

The Buffalo-based cancer hospital will create a new Division of Integrative Immuno-Oncology to develop new personalized therapies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)



Study prompts new ideas on cancers' origins

Fri, 15 Dec 2017 05:00:00 +0100

(Washington University School of Medicine) Cancer therapies often target cells that grow and divide rapidly, such as stem cells, but in studying how stomach cancers occur, researchers at Washington University School of Medicine in St. Louis found that even when the stomach isn't able to make stem cells, other cells in the stomach can begin to divide and contribute to precancerous lesions. (Source: EurekAlert! - Cancer)



'Bet hedging' explains the efficacy of many combination cancer therapies

Thu, 14 Dec 2017 05:00:00 +0100

(Harvard Medical School) Survival benefits of many cancer drug combinations are not due to drug synergy, but to a form of " bet hedging. " Combination treatment gives each patient multiple chances of responding to at least one drug, increasing measures of survival within patient populations. Findings suggest new ways to interpret clinical trial data, identify truly synergistic drug pairings and improve the design of combination therapies. (Source: EurekAlert! - Cancer)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Study reveals breast cancer can return years after the "all clear" – Experts already pushing to keep women on prescriptions longer (no mention of lifestyle)

Tue, 12 Dec 2017 11:10:20 +0100

(Natural News) The findings of a new study out of England have blown yet another hole in the conventional cancer therapy myth, revealing that women who undergo typical procedures like chemotherapy and radiation for breast cancer often see the deadly disease return – in some cases up to 20 years after they were supposedly “cured.”... (Source: NaturalNews.com)



Researchers invent novel RNA nanotech to decorate exosomes for effective cancer therapy

Mon, 11 Dec 2017 05:00:00 +0100

(Ohio State University Wexner Medical Center) A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics specifically to cancer cells. Researchers used RNA nanotechnology to apply the RNA nanoparticles and control their orientation. The microscopic, therapy-loaded extracellular vesicles successfully targeted three types of cancer in animal models. The findings could lead to a new generation of anticancer drugs that use siRNA, microRNA and other RNA-interference technologies. (Source: EurekAlert! - Cancer)



Rapid responses, few adverse effects in targeted agent in Phase1 trial in rare blood disorder

Sun, 10 Dec 2017 05:00:00 +0100

(Dana-Farber Cancer Institute) Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis. Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies. (Source: EurekAlert! - Cancer)



No additional risks from pausing hormone-sensitive breast cancer therapy

Tue, 05 Dec 2017 12:00:00 +0100

According to a study, published inThe Lancet, the effectiveness of breast cancer therapy was not adversely affected by patients taking a break from long-term hormone treatments.News Medical (Source: Society for Endocrinology)



Removing cancer cell debris improves conventional cancer treatments

Mon, 04 Dec 2017 05:00:00 +0100

(Brigham and Women's Hospital) Cancer therapies are designed to kill tumor cells, but produce tumor cell debris in the process. In a study published in The Journal of Experimental Medicine, researchers from Brigham and Women's Hospital and colleagues show that leftover debris can stimulate inflammation and tumor growth, but that molecules called resolvins can block that unwanted inflammatory response. The findings point towards a new way to enhance the effectiveness of current cancer therapies and potentially prevent tumor recurrence. (Source: EurekAlert! - Medicine and Health)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Medical News Today: Killing cancer softly: New approach halts tumor growth

Fri, 01 Dec 2017 08:00:00 +0100

Cancer therapy can sometimes, paradoxically, help the cancer to spread. New research shows why that is, and what can be done to stop it. (Source: Health News from Medical News Today)



Incoming Novartis CEO On $475,000 Cancer Therapy:'No Question That The List Price Raises Eyebrows '

Thu, 30 Nov 2017 13:13:00 +0100

Incoming CEO at Swiss drugmaker Novartis, Vas Narasimhan, said he isn ’t interested in following the herd in drug development. (Source: Forbes.com Healthcare News)



Study reveals cancer therapy's double-edged sword ... and how to blunt it

Thu, 30 Nov 2017 05:00:00 +0100

(Rockefeller University Press) Researchers from Harvard Medical School and the Institute of Systems Biology have discovered that the remains of tumor cells killed by chemotherapy or other cancer treatments can actually stimulate tumor growth by inducing an inflammatory reaction. The study, which will be published Nov. 30 in The Journal of Experimental Medicine, also reveals that a family of molecules called resolvins can suppress this unwanted inflammatory response, suggesting new ways to enhance the effectiveness of existing cancer therapies. (Source: EurekAlert! - Cancer)



Versatile cancer drugs

Thu, 30 Nov 2017 05:00:00 +0100

(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Medications which block enzymes belonging to the kinase family, are among the most effective pharmaceuticals for targeted cancer therapies. Scientists at the German Cancer Consortium (DKTK) at the Technical University of Munich have examined 243 kinase inhibitors which are either approved drugs or have been tested in clinical trials. According to results published in Science, some of these may have more applications than previously thought. (Source: EurekAlert! - Medicine and Health)



Double-edged sword: Killing cancer cells can also drive tumor growth

Thu, 30 Nov 2017 05:00:00 +0100

(Beth Israel Deaconess Medical Center) Cancer therapies including radiation and chemotherapy seek to treat the disease by killing tumor cells. Now a team including researchers at Beth Israel Deaconess Medical Center (BIDMC) have shown that the dead and dying cancer cells generated by chemotherapy and targeted cancer therapy paradoxically trigger inflammation that promotes aggressive tumor growth. In a study published today in the Journal of Experimental Medicine, the team has illuminated the mechanism by which tumor cell death can drive primary tumor growth and metastasis. (Source: EurekAlert! - Medicine and Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Aridis uses human antibodies to fight against “time bomb” of antibiotic resistance

Tue, 21 Nov 2017 13:11:27 +0100

Although antibodies have gained plenty of ground in recent years as vehicles for cancer therapies, Aridis Pharmaceuticals wants to use them as nature intended – to fight infection. “These are human monoclonal antibodies being investigated as anti-infectives to treat bacterial infections associated with pneumonia,” founder & CEO Vu Truong told Drug Delivery Business News, referring to the company’s projects that are in pivotal trials. “The fundamental reason is that this is exactly what the antibody is designed to do – that is, to fight infection,” he explained. Get the full story at our sister site, Drug Delivery Business News. The post Aridis uses human antibodies to fight against “time bomb” of antibiotic resistance appeared first on MassDevice. (...



People willing to trade treatment efficacy for reduced side effects in cancer therapies

Tue, 21 Nov 2017 05:00:00 +0100

(American Society of Hematology) When choosing their preferred treatment, people with chronic lymphocytic leukemia place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology. The study also suggests that factoring out-of-pocket costs into this decision-making process may significantly influence a patient's choice of treatment. (Source: EurekAlert! - Medicine and Health)



Researchers Say Many People Diagnosed With Cancer Suffer From PTSD

Mon, 20 Nov 2017 22:00:47 +0100

BOSTON (CBS) – Many people diagnosed with cancer suffer from post-traumatic stress disorder or PTSD. Researchers in Malaysia looked at almost 500 adults who had been diagnosed with different types of cancer. One in five had developed PTSD within a few months of their diagnosis and some of those still had symptoms four years later. Getting the news that you have cancer can be shocking and the treatment itself can be traumatic. And then some patients continue to live in fear that the cancer will return. Patients with PTSD can have sleep problems, may be more likely to use substances, and may avoid seeking treatment for unrelated health issues for fear that it might trigger traumatic memories about their cancer therapy. So we need to make sure that patients diagnosed with cancer are of...



Targeted Cancer Therapies Bring New Precision Medicine Tools to Anatomic Pathologists and Clinical Laboratories

Mon, 20 Nov 2017 11:00:25 +0100

FDA is streamlining how new diagnostic tests are approved; encourages IVD companies to focus on ‘qualifying biomarkers’ in development of new cancer drugs It is good news for the anatomic pathology profession that new insights into the human immune system are triggering not only a wave of new therapeutic drugs, but also the need for […] (Source: Dark Daily)



Intermittent Letrozole Similar to Continuous Administration for Extended Breast Cancer Therapy

Mon, 20 Nov 2017 07:41:18 +0100

Taking temporary treatment breaks from letrozole following endocrine therapy for breast cancer is associated with similar disease-free survival as taking letrozole continuously, according to... (Source: Physician's First Watch current issue)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Some cancer therapies may provide a new way to treat high blood pressure

Mon, 20 Nov 2017 05:00:00 +0100

(Georgetown University Medical Center) Drugs designed to halt cancer growth may offer a new way to control high blood pressure (hypertension), say Georgetown University Medical Center investigators. The finding could offer a real advance in hypertension treatment because although a number of high blood pressure drugs are now available, they work by different mechanisms that are not suited for all patients. (Source: EurekAlert! - Cancer)



Optimizing Treatment for Castration-Resistant Prostate Cancer Optimizing Treatment for Castration-Resistant Prostate Cancer

Fri, 17 Nov 2017 19:08:05 +0100

Individualizing castration-resistant prostate cancer therapy depends not only on drug profiles but also on patient-related factors. Experts offer a way through the data to reach a clinical decision.Medscape Oncology (Source: Medscape Today Headlines)



Gut microbiome influences efficacy of PD-1based immunotherapy against epithelial tumors

Fri, 17 Nov 2017 10:36:38 +0100

This piece of research is behind the headline: Gut bacteria " boost " cancer therapy. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies).The findings are of interest, but don't have any immediate implications for cancer treatment. (Source: Current Awareness Service for Health (CASH))



Loxo, Bayer to co-develop cancer drugs in up to $1.55 billion deal

Tue, 14 Nov 2017 12:53:31 +0100

(Reuters) - Loxo Oncology Inc will collaborate with Germany's Bayer AG to develop and commercialize two of its cancer therapies, the companies said on Tuesday, in deal that could bring the U.S. drug developer up to $1.55 billion. (Source: Reuters: Health)



Papers of note in Science Translational Medicine 9 (415)

Tue, 14 Nov 2017 00:00:00 +0100

This week’s articles describe a way to combat the negative effects of stress on cancer therapy; a potential target in heart failure; and why nighttime wounds heal more slowly than daytime wounds. (Source: Signal Transduction Knowledge Environment)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Q & amp;A: How to Prepare for an AI-Driven Future

Tue, 07 Nov 2017 14:55:30 +0100

For years the role of robotics and artificial intelligence within the realm of medtech has been hyped as the future of innovation and device development. Now that technological advances are beginning to catch up to our imagination, how will advanced robotic and AI technologies begin to reshape the medtech landscape?  Srihari Yamanoor With advances in machine learning and robotic design, artificial intelligence is poised to have a dramatic impact on the medical device field. With innovative opportunities on both the diagnostic and therapeutic sides of medicine, AI technologies could be the key that unlocks an entirely new generation of transformative medical device technologies. Srihari Yamanoor is a research and design specialist with extensive experience in medical device de...



Can cannabinoids be used to treat cancer?

Mon, 06 Nov 2017 09:00:00 +0100

When cannabinoids activate signaling pathways in cancer cells they can stimulate a cell death mechanism called apoptosis, unleashing a potent anti-tumor effect. Yet cannabinoids, which have also shown strong activity against human tumor tissue grown in animal models, have undergone minimal testing in patients. Their potential use as antitumor drugs and/or to boost the effectiveness of conventional cancer therapies is examined in an article published in The Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. (Source: World Pharma News)



Cancer treatment response may be affected by gut bacteria

Fri, 03 Nov 2017 17:00:00 +0100

Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of particular bacteria improves people's responses to immunotherapy, or whether the immunotherapy somehow influences the levels of specific bacteria. It's unclear whether the f...



Gut bacteria 'boost' cancer therapy

Fri, 03 Nov 2017 00:53:45 +0100

Trials suggest the trillions of micro-organisms living in us alter immunotherapy's effectiveness. (Source: BBC News | Health | UK Edition)



Breast cancer patients forego post-surgery treatment due to mistrust, study suggests

Wed, 01 Nov 2017 04:00:00 +0100

(Johns Hopkins University Bloomberg School of Public Health) Nearly one-third of women with breast cancer went against their doctor's advice and chose not to begin or complete the recommended adjuvant anti-cancer therapy to kill residual tumor cells following surgery, according to a study led by a Johns Hopkins Bloomberg School of Public Health researcher. (Source: EurekAlert! - Cancer)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Incyte, AstraZeneca expand collaboration on potential lung cancer therapy

Tue, 31 Oct 2017 16:52:24 +0100

Incyte Corp. is expanding its clinical collaboration with MedImmune, AstraZeneca's global biologics research and development arm. As part of the expanded agreement, the two companies will evaluate the effectiveness and safety of a combination therapy — featuring one product from each company — in treating patients with non-small cell lung cancer. The phase-III study of the treatment pairing Incyte's investigational enzy me inhibitor called epacadostat with AstraZeneca's Imfinzi human monoclonal… (Source: bizjournals.com Health Care:Biotechnology headlines)



Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy

Mon, 30 Oct 2017 11:00:00 +0100

Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology therapies. The new effort combines Boehringer Ingelheim's oncology research and Sarah Cannon’s expertise in clinical trial design and recruitment to evaluate BI 891065, a novel and potent SMAC mimetic, alone and as a potential combination partner with PD-1-directed cancer therapy. (Source: World Pharma News)



NovoCure rises on Q3 EPS, sales beat

Thu, 26 Oct 2017 13:50:16 +0100

Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. “The third quarter of 2017 was another period marked by growth across all key commercial metrics in all key markets. Compared to the same quarter in 2016, we achieved 131% revenu...



Incyte enters into licensing deal valued at up to $900M

Wed, 25 Oct 2017 16:35:28 +0100

Incyte Corp. obtained worldwide rights to an experimental cancer therapy Wednesday under a collaboration and licensing agreement it signed with a Maryland biotechnology company. Under the terms of the deal, Incyte of Wilmington, Del., will make an upfront payment of $150 million to MacroGenics. MacroGenics of Rockville, Md., could receive up to $420 million in potential development and regulatory milestones, and up to $330 million in potential commercial milestones. If t he new drug candidate licensed… (Source: bizjournals.com Health Care:Biotechnology headlines)



New study: 'Double decker' antibody technology fights cancer

Wed, 25 Oct 2017 04:00:00 +0100

(Scripps Research Institute) Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates for cancer therapy. (Source: EurekAlert! - Biology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




NEHI urges prompt action to enable value-based contracts for innovative, high cost cancer therapies

Tue, 24 Oct 2017 04:00:00 +0100

(NEHI (the Network for Excellence in Health Innovation)) NEHI (the Network for Excellence in Health Innovation) called today for a series of regulatory steps and other actions to enable new payment arrangements for high cost cancer drugs. (Source: EurekAlert! - Biology)



Rockville-based cancer therapy company CytImmune Sciences in fundraising mode

Mon, 23 Oct 2017 11:54:42 +0100

The company is working on a therapy for pancreatic cancer using nanotechnology. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)



FDA Approves Landmark Cancer Therapy; Wilmot Positioned Among First to Offer It

Fri, 20 Oct 2017 18:11:29 +0100

UR Medicine ’s Wilmot Cancer Institute will be among the first sites in the world to offer CAR T-cell therapy —a new type of immunotherapy—to adults with aggressive lymphoma. The engineered gene therapy has been described as a revolutionary “living drug” and one of the most powerful cancer treatments to emerge in recent years. (Source: University of Rochester Medical Center Press Releases)



Rockville-based cancer therapy company Cytimmune Sciences in fundraising mode

Fri, 20 Oct 2017 09:16:40 +0100

The company is working on a therapy for pancreatic cancer using nanotechnology. (Source: bizjournals.com Health Care News Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Suicide molecules kill any cancer cell

Thu, 19 Oct 2017 04:00:00 +0100

(Northwestern University) A super assassin hidden in every cell forces the cell to commit suicide if it becomes cancerous, reports a new study, the first to identify molecules to trigger a fail-safe mechanism that may protect us from cancer. The mechanism -- RNA suicide molecules -- can potentially be developed into a novel form of cancer therapy. Cancer cells treated with the RNA molecules never become resistant to them because they simultaneously eliminate multiple genes that cancer cells need for survival. (Source: EurekAlert! - Cancer)



Gilead new cancer therapy wins FDA approval — with $373,000 tag

Wed, 18 Oct 2017 23:30:42 +0100

(Source: FT.com - Drugs and Healthcare)



Researchers release the brakes on the immune system

Tue, 17 Oct 2017 04:00:00 +0100

(University of Bonn) Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural 'brakes' in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes. The study, which involved colleagues from Hamburg and W ü rzburg, could pave the way for more effective cancer therapies. It is being published in the journal Cell Reports. (Source: EurekAlert! - Cancer)



Immunotherapy Side Effects: New Global Guidelines for Nurses Immunotherapy Side Effects: New Global Guidelines for Nurses

Mon, 16 Oct 2017 11:46:16 +0100

Immunotherapy has revolutionized cancer therapy, but these drugs have unique and sometimes life-threatening adverse events, as outlined in the new guidelines.Medscape Medical News (Source: Medscape Medical News Headlines)



Vanderbilt researchers find novel mechanism of resistance to anti-cancer drugs

Mon, 16 Oct 2017 04:00:00 +0100

(Vanderbilt University Medical Center) Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported Oct. 16 in Nature Medicine, suggest a strategy for overcoming this resistance. (Source: EurekAlert! - Cancer)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




US NIH launches $215m Partnership for Accelerating Cancer Therapies

Sun, 15 Oct 2017 23:00:00 +0100

The US National Institutes of Health (NIH), along with 11 biopharmaceutical companies, has launched a $215m five-year public-private research collaboration to advance new cancer immunotherapy strategies for more patients. (Source: Pharmaceutical Technology)



NIH Partners With 11 Drugmakers to Accelerate Cancer Therapy Research NIH Partners With 11 Drugmakers to Accelerate Cancer Therapy Research

Fri, 13 Oct 2017 20:09:25 +0100

The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body's immune system to fight cancer.Reuters Health Information (Source: Medscape Today Headlines)



A range of substances with antitumor properties was synthesized at RUDN University

Fri, 13 Oct 2017 04:00:00 +0100

(RUDN University) Scientists from RUDN University have synthesized a number of new cytotoxic substances - the ones that can damage cells. In the future the results of the study can be used in cancer therapy. The compounds were obtained by domino reaction, a successive formation of several new chemical bonds. The study was published in the Synthesis journal (Source: EurekAlert! - Cancer)



U.S. NIH, 11 drugmakers partner to accelerate cancer therapy research

Thu, 12 Oct 2017 16:34:24 +0100

(Reuters) - The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. (Source: Reuters: Health)



PhRMA, member companies and NIH create public-private partnership for immuno-oncology

Thu, 12 Oct 2017 16:15:28 +0100

The rapid pace of scientific advances has helped usher in anew era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took asignificant step in advancing this new era by partnering with PhRMA and nine of its member companies to create the Partnership for Accelerating Cancer Therapies (PACT), a five-year research collaboration totaling $215 million as part of the Cancer Moonshot initiative. This public-private partnership will be managed by the Foundation for the National Institutes of Health. (Source: The Catalyst)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




NIH partners 11 drugmakers to accelerate cancer therapy research

Thu, 12 Oct 2017 14:05:53 +0100

(Reuters) - The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body's immune system to fight cancer. (Source: Reuters: Health)



NIH, 11 biopharmaceutical companies partner to speed development of cancer immunotherapy strategies

Thu, 12 Oct 2017 04:00:00 +0100

(NIH/Office of the Director) The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers -- standardized biological markers of disease and treatment response -- to advance new immunotherapy treatments that harness the immune system to attack cancer. (Source: EurekAlert! - Social and Behavioral Science)



Cleveland Clinic researchers reveal biomarker for guiding prostate cancer treatment

Thu, 12 Oct 2017 04:00:00 +0100

(Cleveland Clinic) Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the Oct. 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized treatment plan that targets specific hormonal pathways. (Source: EurekAlert! - Cancer)



Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development

Fri, 06 Oct 2017 13:16:25 +0100

TAMPA, Fla., Oct. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Intezyne Technologies, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it closed an oversubscribed $10M Series A Preferred round lead ... Biopharmaceuticals, Oncology, Venture Capital, Personnel Intezyne Technologies, Cancer Resistance Pathway (Source: HSMN NewsFeed)



'Smart' immune cells: Emerging cancer therapy research boosted with NIH award

Thu, 05 Oct 2017 04:00:00 +0100

(University of California - Davis) Assistant Professor Sean Collins, Department of Microbiology and Molecular Genetics in the UC Davis College of Biological Sciences, has received a $1.5 million award from the National Institutes of Health to advance the development of 'smart' immune cells for therapies to treat cancer and other diseases. The five-year NIH Director's New Innovator Award aims to provide new insight into how to engineer immune cells to control their recruitment and response to tumors. (Source: EurekAlert! - Biology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Colorectal Cancer Therapy Gets a Tune-up: ESMO 2017 Colorectal Cancer Therapy Gets a Tune-up: ESMO 2017

Mon, 02 Oct 2017 14:11:38 +0100

Although not a year for big advances in colorectal cancer, exciting research with current standards was presented at ESMO 2017.Medscape Oncology (Source: Medscape Today Headlines)



A new approach to cancer drug discovery

Fri, 29 Sep 2017 10:00:00 +0100

Scientists at The Scripps Research Institute (TSRI) have developed and demonstrated a promising new strategy for the discovery of novel anti-cancer therapies. The TSRI scientists, collaborating with scientists at Pfizer, used their new approach to find small-molecule inhibitors of a protein that is important for the growth of non-small-cell lung cancers (NSCLCs). These cancers represent about 85 percent of lung cancers and are relatively insensitive to drug treatment. (Source: World Pharma News)



Pfizer helps pump $103M into startup to develop new cancer therapies

Tue, 26 Sep 2017 12:52:29 +0100

A New York startup has been spun-out of Pfizer to develop clinical-stage experimental therapies. Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology). Pfizer (NYSE: PFE) granted SpringWorks the rights to help develop four drugs or t herapies that treat various conditions, including post-traumatic stress disorder and cancer. Another New… (Source: bizjournals.com Health Care:Biotechnology headlines)



New approaches in targeted cancer therapy

Tue, 26 Sep 2017 04:00:00 +0100

(University of Cologne) In a large-scale testing procedure, scientists from Cologne University Hospital have explored the effects of more than 1,500 substances on different kinds of cancer cells. The results from this study are a fundamental prerequisite for the development of new therapies for NMC, an aggressive cancer which is often lethal. (Source: EurekAlert! - Cancer)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Pfizer helps pump $103M into startup to develop new cancer therapies

Mon, 25 Sep 2017 15:55:24 +0100

A local startup has been spun-out of Pfizer to develop clinical-stage experimental therapies. Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology). Pfizer (NYSE: PFE) granted SpringWorks the rights to help develop four drugs or t herapies that treat various conditions, including post-traumatic stress disorder and cancer. Another New York-based… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)



Photoacoustic imaging and photothermal cancer therapy using BR nanoparticles

Mon, 25 Sep 2017 04:00:00 +0100

(The Korea Advanced Institute of Science and Technology (KAIST)) Sangyong Jon, a professor in the Department of Biological Sciences at KAIST, and his team developed combined photoacoustic imaging and photothermal therapy for cancer by using Bilirubin (BR) nanoparticles.The team expects this research, which shows high biocompatibility as well as outstanding photoacoustic imaging and photothermal therapy, to be an appropriate system in the field of treatment for cancer. (Source: EurekAlert! - Cancer)



Hearst invests $75 million in Moffitt's M2Gen

Wed, 20 Sep 2017 11:16:24 +0100

M2Gen, a Moffitt Cancer Center subsidiary that uses big data to find ways to treat cancer, is receiving a $75 million equity investment from Hearst. The partnership will help accelerate the discovery of innovative cancer therapies and improve care for patients nationwide, Hearst said in a press release. The press release did not disclose the amount of the investment, but a Moffitt spokeswoman confirmed it was $75 million. Hearst invests in c ompanies working to improve and advance health care,… (Source: bizjournals.com Health Care News Headlines)



Penn researchers identify new target, develop new drug for cancer therapies

Wed, 20 Sep 2017 04:00:00 +0100

(University of Pennsylvania School of Medicine) Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to target that enzyme resistant to treatment. Researchers were able to use this finding to develop a drug that successfully inhibits tumor growth of melanoma as well as pancreatic and colorectal cancer in mice. (Source: EurekAlert! - Cancer)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Mesothelioma Clinical Trials Involve Gene Therapy

Tue, 19 Sep 2017 18:03:44 +0100

Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen receptor (CAR) T cell therapy, which includes removing T cells from a patient, arming them with a protein linked to a particular cancer and then returning those cells to the pati...



Cancer Treatment Can Affect Your Food Preferences

Tue, 19 Sep 2017 14:09:44 +0100

TUESDAY, Sept. 19, 2017 -- Cancer therapies often change patients'sense of taste, which may affect what they like to eat, according to a nutrition expert. " Increased taste sensitivities are more common than a muting of taste, " said Catherine... (Source: Drugs.com - Daily MedNews)



New cancer care 'passport' for London ’s nurses launched

Fri, 15 Sep 2017 11:24:00 +0100

A “cancer care passport” has been launched for the capital’s oncology specialist nurses, so they can demonstrate they are qualified and competent to deliver systemic anti-cancer therapy (SACT). (Source: Nursing Times)



Debugging a cancer therapy

Thu, 14 Sep 2017 00:00:00 +0100

(Source: ScienceNOW)



Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Thu, 14 Sep 2017 00:00:00 +0100

Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2',2'-difluorodeoxycytidine) into its inactive form, 2',2'-difluorodeoxyuridine. Metabolism was dependent on the expression of a long isoform of the bacterial enzyme cytidine deaminase (CDDL), seen primarily in Gammaproteobacteria. In a colon cancer mouse model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of th...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.